J9017 HCPCS code: Injection, arsenic trioxide, 1 mg
J9017 is the HCPCS Level II code for injection, arsenic trioxide, 1 mg. In 2024 Medicare paid an average of $9.36 per service for J9017 across 36,889 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 30 per day on outpatient hospital claims. Medicare volume rose 58% from 2022 to 2024 (23,388 to 36,889 services). In 2024, about 261 clinicians billed Medicare for J9017 for 51 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2002-01-01 |
| Last action effective | 2009-01-01 |
Who bills J9017 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 261 |
| Medicare beneficiaries | 51 |
| States with claims | 0 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9017, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 23,388 | 41 | $13.45 | $10.72 |
| 2023 | 30,383 | 47 | $14.80 | $11.79 |
| 2024 | 36,889 | 51 | $11.79 | $9.36 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 30 | Clinical: Data |
| practitioner claims | 30 | Clinical: Data |
What changed for J9017
- 2002-01-01: J9017 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9017?
J9017 is the HCPCS Level II code for injection, arsenic trioxide, 1 mg. Short descriptor: "Arsenic trioxide injection".
How much does Medicare pay for J9017?
In 2024, the average Medicare payment was $9.36 per service (average allowed $11.79).
Does Medicare cover J9017?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9017 can be billed per day?
30 on outpatient hospital claims; 30 on practitioner claims (NCCI medically unlikely edits).
Related J90 codes
- J9000 — Injection, doxorubicin hydrochloride, 10 mg
- J9003 — Leuprolide injectable (camcevi etm), 1 mg
- J9010 — Injection, alemtuzumab, 10 mg
- J9011 — Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015 — Injection, aldesleukin, per single use vial
- J9019 — Injection, asparaginase (erwinaze), 1,000 iu
- J9020 — Injection, asparaginase, not otherwise specified, 10,000 units
- J9021 — Injection, asparaginase, recombinant, (rylaze), 0.1 mg
- J9022 — Injection, atezolizumab, 10 mg
- J9023 — Injection, avelumab, 10 mg
- J9024 — Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
- J9025 — Injection, azacitidine, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9017
- Watch J9017 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9017
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.